



Ellen Frank, PhD  
Chief Scientific Officer and Co-founder  
HealthRhythms, Inc.


Dear Ellen,

Thank you for reaching out to me to share my perspective on HealthRhythms' work. Please feel free to share my letter as part of your Prix Galien submission for best startup of 2023. I know you and HealthRhythms first-hand by having utilized your software in one of the critical drug development programs my team has led. The methodology your company has developed is addressing key challenges we face in developing and evaluating new psychopharmacological treatments: measuring patient symptomatology in an objective manner, eliminating the restrictions of traditional measurement methods that rely on a clinician-patient dialogue which typically is limited to weekly assessments, covers only a limited time period and is inherently subjective, both on the part of the patient and on the part of the clinician.

Your development of smartphone-based digital biomarkers represents a unique methodology and will empower a much richer understanding of patients, patient sub-groups, and treatment response. In addition to the unique advantages mentioned above, HealthRhythms' behavioral biomarkers represent can generate passively acquired data over extended observational periods to study long-term treatment impact. Any self-report measure presented over periods of months or even years will inevitably degrade in quality. Your approach does not.

As drug developers, we strive to bring the most efficacious and safest treatments to patients – in my opinion HealthRhythms is on a path of providing an essential tool set with breakthrough potential for mental health assessment and the faster development of novel treatment options. Congratulations on HealthRhythms' accomplishments to date.

Best wishes for HealthRhythms' continued success,



Best regards,  
Jeffrey M Jonas MD  
CEO ABIO-X